1.
Bioorg Med Chem Lett
; 20(12): 3713-6, 2010 Jun 15.
Artigo
em Inglês
| MEDLINE
| ID: mdl-20471831
RESUMO
Antagonists of the 5-HT(6) receptor have been shown to improve cognitive function in a wide range of animal models and as such may prove to be attractive agents for the symptomatic treatment of cognitive disorders such as Alzheimer's disease (AD) and schizophrenia. We report herein the identification and SAR around N-(2-aminoalkyl)-1-(arylsulfonyl)indoline-3-carboxamides-a novel chemotype of 5-HT(6) antagonists.